HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis - 23/02/18
, John Gregson, PhD c, Neil Parkin, PhD d, Hiwot Haile-Selassie, MD e, Amilcar Tanuri, ProfPhD f, Liliana Andrade Forero, MD g, Pontiano Kaleebu, ProfPhD h, i, Christine Watera, MSc h, i, Avelin Aghokeng, PhD j, k, Nicholus Mutenda, MD l, Janet Dzangare, MD m, San Hone, MD n, Zaw Zaw Hang, MD n, Judith Garcia, MD o, Zully Garcia, MD p, Paola Marchorro, MD q, Enrique Beteta, MD r, Amalia Giron, MD s, Raph Hamers, MD t, u, Seth Inzaule, MSc t, u, Lisa M Frenkel, ProfMD v, w, Michael H Chung, MD x, Tulio de Oliveira, ProfPhD y, z, Deenan Pillay, ProfFRCPath a, b, Kogie Naidoo, PhD z, aa, Ayesha Kharsany, ProfMD z, Ruthiran Kugathasan, MRCP ab, Teresa Cutino, FRCP ab, Gillian Hunt, PhD ac, Santiago Avila Rios, PhD ad, Meg Doherty, MD e, Michael R Jordan, MD ae, af, Silvia Bertagnolio, MD eSummary |
Background |
Pretreatment drug resistance in people initiating or re-initiating antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and middle-income countries (LMICs). We aimed to assess the scale of this problem and whether it is associated with the intiation or re-initiation of ART in people who have had previous exposure to antiretroviral drugs.
Methods |
This study was a systematic review and meta-regression analysis. We assessed regional prevalence of pretreatment drug resistance and risk of pretreatment drug resistance in people initiating ART who reported previous ART exposure. We systematically screened publications and unpublished datasets for pretreatment drug-resistance data in individuals in LMICs initiating or re-initiating first-line ART from LMICs. We searched for studies in PubMed and Embase and conference abstracts and presentations from the Conference on Retroviruses and Opportunistic Infections, the International AIDS Society Conference, and the International Drug Resistance Workshop for the period Jan 1, 2001, to Dec 31, 2016. To assess the prevalence of drug resistance within a specified region at any specific timepoint, we extracted study level data and pooled prevalence estimates within the region using an empty logistic regression model with a random effect at the study level. We used random effects meta-regression to relate sampling year to prevalence of pretreatment drug resistance within geographical regions.
Findings |
We identified 358 datasets that contributed data to our analyses, representing 56 044 adults in 63 countries. Prevalence estimates of pretreatment NNRTI resistance in 2016 were 11·0% (7·5–15·9) in southern Africa, 10·1% (5·1–19·4) in eastern Africa, 7·2% (2·9–16·5) in western and central Africa, and 9·4% (6·6–13·2) in Latin America and the Caribbean. There were substantial increases in pretreatment NNRTI resistance per year in all regions. The yearly increases in the odds of pretreatment drug resistance were 23% (95% CI 16–29) in southern Africa, 17% (5–30) in eastern Africa, 17% (6–29) in western and central Africa, 11% (5–18) in Latin America and the Caribbean, and 11% (2–20) in Asia. Estimated increases in the absolute prevalence of pretreatment drug resistance between 2015 and 2016 ranged from 0·3% in Asia to 1·8% in southern Africa.
Interpretation |
Pretreatment drug resistance is increasing at substantial rate in LMICs, especially in sub-Saharan Africa. In 2016, the prevalence of pretreatment NNRTI resistance was near WHO’s 10% threshold for changing first-line ART in southern and eastern Africa and Latin America, underscoring the need for routine national HIV drug-resistance surveillance and review of national policies for first-line ART regimen composition.
Funding |
Bill & Melinda Gates Foundation and World Health Organization.
Le texte complet de cet article est disponible en PDF.Plan
Vol 18 - N° 3
P. 346-355 - mars 2018 Retour au numéro
Article précédent
- Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study
- Roberto Amato, Richard D Pearson, Jacob Almagro-Garcia, Chanaki Amaratunga, Pharath Lim, Seila Suon, Sokunthea Sreng, Eleanor Drury, Jim Stalker, Olivo Miotto, Rick M Fairhurst, Dominic P Kwiatkowski
- Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives
- Laurent Abel, Jacques Fellay, David W Haas, Erwin Schurr, Geetha Srikrishna, Michael Urbanowski, Nimisha Chaturvedi, Sudha Srinivasan, Daniel H Johnson, William R Bishai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?